Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03031730 · OUTCOME

Evaluate Safety and Tolerability of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomdie, and Dexamethasone (KRd)

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma · Source last updated 2026-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Dose Limiting Toxicity
Interval / dispersion
Not reported
Time frame
at least 6 months of treatment, an average of 1 year

Analysis population: Only included DLT-evaluable patients. 6 of 6 patients enrolled on Dose Level 1 and 5 of 10 patients at dose level 2 were DLT-evaluable. Therefore, the primary outcome of determining the safety and tolerability beyond dose level one was not possible, and the MTD and recommended phase 2 dose could not be evaluated prior to study closure.

Groups in this outcome

Part A: Dose Level 1

KRT-232 60 mg + KRd

Part A: Dose Level 2

KRT-232 90 mg + KRd

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A: Dose Level 16
Part A: Dose Level 25

Reported measurements

Source class 1
Values in Dose Limiting Toxicity · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part A: Dose Level 11Not reportedNot reportedNot reportedNot reported
Part A: Dose Level 21Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      5
    units
    Participants
groups
  1. description
    KRT-232 60 mg + KRd
    id
    OG000
    title
    Part A: Dose Level 1
  2. description
    KRT-232 90 mg + KRd
    id
    OG001
    title
    Part A: Dose Level 2
param Type
NUMBER
population Description
Only included DLT-evaluable patients. 6 of 6 patients enrolled on Dose Level 1 and 5 of 10 patients at dose level 2 were DLT-evaluable. Therefore, the primary outcome of determining the safety and tolerability beyond dose level one was not possible, and the MTD and recommended phase 2 dose could not be evaluated prior to study closure.
reporting Status
POSTED
time Frame
at least 6 months of treatment, an average of 1 year
title
Evaluate Safety and Tolerability of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomdie, and Dexamethasone (KRd)
type
PRIMARY
unit Of Measure
Dose Limiting Toxicity

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice